The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist
Open accessAbstract
Summary: The clinical pharmacology profile of a drug critically determines its therapeutics, and this review summarizes the characteristics associated with the antiepileptic drug (AED) perampanel. A PubMed literature search was performed for perampanel. Congress abstract data are included where necessary and Eisai Ltd provided access to unpublished data on file. After oral ingestion, perampanel is rapidly absorbed and peak plasma concentrations occur 0.5–2.5 h later; its bioavailability is ~100%. Although the rate of perampanel absorption is slowed by food co‐ingestion, the extent absorbed remains unchanged; therefore, perampanel can be administered without regard to meal times. The pharmacokinetics of perampanel are linear and predictable over the clinically relevant dose range (2–12 mg); perampanel is 95% protein‐bound to albumin and α1‐acid glycoprotein. Perampanel is extensively metabolized (>90%) in the liver, primarily by cytochrome P450 (CYP) 3A4, to various pharmacologically inactive metabolites. In healthy volunteers, the apparent terminal half‐life is ~105 h, whereas the calculated effective half‐life is 48 h. These half‐life values allow for once‐daily dosing, which will aid patient compliance and in the event of a missed dose, will have minimal impact on seizure control. In healthy volunteers prescribed carbamazepine, half‐life decreases to 25 h. Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min). Perampanel has minimal propensity to cause pharmacokinetic interactions. However, it is the target of such interactions and CYP3A4‐inducing AEDs enhance its clearance; this can be used to advantage because dose titration can be faster and thus optimum therapeutic outcome can be achieved sooner. Perampanel 12 mg, but not 4 or 8 mg, enhances the metabolism of the progesterone component of the oral contraceptive pill, necessitating the need for an additional reliable contraceptive method. Overall, perampanel has a favorable clinical pharmacology profile, which should aid its clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01561.x · Cited by 1,156
Self-citationPatterns of treatment response in newly diagnosed epilepsy
Brodie, M. J., Barry, S. J. E., Bamagous, G. A., Norrie, J. D., & Kwan, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563b19 · Cited by 931
Changes in plasma protein binding have little clinical relevance
Benet, L. Z., & Hoener, B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121829 · Cited by 825
Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 479
Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures
Krauss, G. L., Serratosa, J. M., Villanueva, V., Endziniene, M., Hong, Z., French, J., Yang, H., Squillacote, D., Edwards, H. B., Zhu, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318254473a · Cited by 431
Refractory Epilepsy: Clinical Overview
French, J. A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00992.x · Cited by 430
French, J. A., Krauss, G. L., Steinhoff, B. J., Squillacote, D., Yang, H., Kumar, D., & Laurenza, A. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03638.x · Cited by 423
Patsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00409-5 · Cited by 423
Self-citationHanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., Hatakeyama, S., Ohgoh, M., Ueno, M., & Nishizawa, Y. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03109.x · Cited by 411
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update
Patsalos, P. N., Spencer, E. P., & Berry, D. J. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000546 · Cited by 477
Self-citation
Metadata
- Authors
- Patsalos, P. N.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2014-12-13
- Volume
- 56
- Issue
- 1
- Pages
- 12-27
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2083402697
- Cited by
- 272
- References
- 22
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. https://app.cochat.ai/papers/10.1111/epi.12865
- The paper
- Patsalos, P. N. (2015). The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. https://doi.org/10.1111/epi.12865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.